New Evidence Links Labetalol and High-Dose Atorvastatin to Rare Liver Injury

Recent publications highlight rare but potentially severe drug-induced liver injury associated with two commonly used cardiovascular medications: labetalol, a first-line antihypertensive in pregnancy, and atorvastatin, a widely prescribed statin. The reports include a fatal case and systematic review of labetalol-associated hepatotoxicity, and a case of hyperacute liver failure following high-dose atorvastatin that resolved after drug discontinuation.

Labetalol is widely prescribed as a first-line antihypertensive in pregnancy; however, rare but potentially severe idiosyncratic hepatotoxicity has been reported, with a disproportionately strong reporting signal for liver injury relative to other β-blockers. In an analysis published in The Journal of Clinical Pharmacology, a fatal case is described in which mild initial symptoms rapidly progressed to fulminant hepatocellular injury and acute liver failure within days.

A PRISMA-guided systematic review of MEDLINE, Embase, CINAHL, Cochrane Library, PubMed, and Google Scholar (from inception to December 2025) identified 27 published case reports. Patients were predominantly female (≈80%), and one-third were pregnant or postpartum. Latency ranged from 7 to 365 days (median ≈60 days). The injury phenotype was consistently hepatocellular, often with autoimmune-like serologic or histologic features. Outcomes included full recovery in most (≈75%), but also liver transplantation and death.

In the FDA Adverse Event Reporting System (2020Q1-2025Q1), labetalol showed strong disproportionality signals for drug-induced liver injury (PRR 22.7, 95% CI 15.6-33.1; ROR 23.7, 95% CI 16.0-35.1; IC025 2.5) and autoimmune hepatitis (PRR 59.8, 95% CI 34.1-104.8; ROR 60.9, 95% CI 34.4-108.1; IC025 2.8), which persisted when restricted to other β-blockers as comparators. Signals for acute hepatic failure and hyperbilirubinemia were elevated but less statistically robust. The authors concluded that the available evidence is consistent with a clinically meaningful and biologically plausible association between labetalol and idiosyncratic hepatotoxicity.

In a separate case report published in Cureus, a male patient in his seventies developed hyperacute hepatic failure within 24 hours of initiating atorvastatin 80 mg for secondary stroke prevention. Extensive investigations ruled out alternative causes, and his condition rapidly improved after discontinuation, implicating drug-induced liver injury. The report notes that clinically significant statin-induced hepatotoxicity is rare and has been more frequently reported with higher doses, particularly 80 mg daily. Onset of liver injury is variable, most commonly occurring within the first six months of therapy or following a dose escalation. The case highlights the unpredictable nature of statin-induced hepatotoxicity, emphasizing the need for vigilance, particularly in elderly patients with comorbidities.